Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 250 participants.

Also called NCT05457933

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 250 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05457933
Other papers using this trial's data
  • Dapagliflozin for inpatient hyperglycemia in cardiac surgery patients with type 2 diabetes: randomised controlled trial (Dapa-Hospital trial) Acta diabetologica, 2023-11 DOI, PubMed 37380728

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
India (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05457933. Randomized; no masking; primary purpose treatment. Start 2022-07-29 (actual); primary completion 2023-01-14 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes
Condition
Type2diabetes
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Glargine
Lead sponsor
Medanta, The Medicity, India (class: other)

Record details

Record id
cardio:ct-nct05457933
Content hash
0857a27271e02f71f6ea4cd6da005b3824b901e2f4af11538a6bf583b226f5a1